Neumora Therapeutics, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Neumora Therapeutics, Inc. now
Current reporting with the operating signal separated from the noise.
Perceptive Advisors LLC Takes $9.95 Million Position in Neumora Therapeutics, Inc. $NMRA
The story matters when it changes Neumora Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Moderate Buy" from Brokerages
The story matters when it changes Neumora Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Neumora Therapeutics, Inc. Revenue Breakdown – NASDAQ:NMRA
Investors are testing whether Neumora Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Neumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call Transcript
Investors are testing whether Neumora Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Neumora Therapeutics, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Neumora Therapeutics, Inc. Shareholders of Deadline in Securities Fraud Class Action ...
Investors are testing whether Neumora Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Neumora Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights
The story matters when it changes Neumora Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights
The story matters when it changes Neumora Therapeutics, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode
Investors are testing whether Neumora Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Neumora Therapeutics, Inc. (NMRA) Q3 2024 Earnings Call Transcript
Investors are testing whether Neumora Therapeutics, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest NMRA filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Neumora Therapeutics, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
SEARCH Q2 COVERAGE →Third quarter
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →